A quiet analytical research laboratory at night, racks of glass vials along a dim bench.

Tissue Repair and Recovery: What Is Proven and What Is Not

Tissue repair is the health area with the widest gap between online interest and approved evidence. One growth factor (becaplermin) is FDA approved for a narrow wound indication; the peptides most discussed for recovery, BPC-157 and TB-500, have evidence largely limited to animal studies and are prohibited in sport. Vegalab maps that gap honestly and works only on lawful formats.

Repair biology

Soft tissue healing runs through overlapping phases: hemostasis, inflammation, proliferation (fibroblast migration, angiogenesis, new collagen) and remodeling, which can last a year in tendon and ligament. Growth factors (PDGF, VEGF, TGF-beta), matrix metalloproteinases and copper-dependent enzymes such as lysyl oxidase all participate. Poorly vascularized tissues like tendon heal slowly, which is why local delivery and residence time matter as much as the active itself. Delivery design must therefore match the phase and the tissue, not just the molecule.

Evidence tier by compound

Becaplermin gel (recombinant PDGF-BB) is FDA approved for diabetic neuropathic foot ulcers. BPC-157, a 15-amino-acid fragment of a gastric protein, is not approved as a drug in any major market, and published efficacy data are almost entirely from rodent models. Thymosin beta-4 fragments (sold as TB-500) have a similar profile. GHK-Cu, a copper tripeptide, is an established cosmetic ingredient with in vitro and topical data on collagen synthesis. Collagen peptides are food and supplement ingredients.

Sport, law and delivery

BPC-157 is listed under S0 (non-approved substances) and TB-500 under S2 on the WADA Prohibited List, so neither may appear in products for athletes. In the US, unapproved peptides cannot be marketed for human use as supplements. Where a lawful route exists, as with GHK-Cu in topical cosmetics, the delivery problem is skin penetration of a charged, hydrophilic peptide; see the skin penetration challenge and the Beauty Science pages for that work.

Key facts

Becaplermin (Regranex) gel is FDA approved as an adjunct for lower extremity diabetic neuropathic ulcers (FDA label, Regranex 1997)
BPC-157 is prohibited at all times under category S0 of the WADA Prohibited List (WADA Prohibited List 2026, S0)
Thymosin beta-4 and its derivatives, including TB-500, are prohibited at all times under category S2 (WADA Prohibited List 2026, S2.3)
GHK-Cu stimulates collagen and glycosaminoglycan synthesis in fibroblast studies and is used in topical cosmetics (Pickart and Margolina 2018, Int J Mol Sci 19:1987)

How our delivery technology applies

For repair peptides the obstacles are proteolysis, rapid clearance and poor penetration of skin or mucosa. Multi-layer encapsulation can shield a peptide from enzymes in a topical or oral matrix and extend residence at the application site through mucoadhesive outer layers. Vegalab applies this only to lawful formats, principally cosmetic GHK-Cu and approved or investigational actives developed with licensed partners.

Develop a lawful repair or recovery format with a licensed partner: contact our team.